Nice Article. i am long AMRN..Donno why AMRN started for a BP in the first place with just MARINE indication, when they know that they can get better price after ANCHOR approval..it's one of the reasons for stock to slide by putting BO expectation on the market besides delay in GIA, NCE and insider sales. with this current model, the PPS is at 1.2B, could you please share your thoughts on the anchor model, where the pps might stand or could possibly move during the next year? (assuming with good efficacy profile and a decent marketing of the drug)..Thanks..
4 Biotech Stocks With Important Catalysts Approaching [View article]
Nice article..i like the way you have highlighted things and told everyone to stay away from them which is in a way true as well..anyways, i am long AMRN and head over heels in it..so, can't get out now..just curious the sales potential of 1.8 B by 2018..does that include ANCHOR and REDUCE-IT as well or just MARINE..somehow, I feel that ANCHOR is not priced in..could you please share your insights on this?
Buy Amarin: Huge Upside Despite Commercialization Efforts [View article]
Buy Amarin: Huge Upside Despite Commercialization Efforts [View article]
Buy Amarin: Huge Upside Despite Commercialization Efforts [View article]
4 Biotech Stocks With Important Catalysts Approaching [View article]